Phase III MEL 1L, PD-1 vs Ipi vs. PD-1 Ipi
Research payments
$1,421,711
Through program year 2021, $1,421,711 in research payments was reported against Phase III MEL 1L, PD-1 vs Ipi vs. PD-1 Ipi, across 86 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $207,226 | 28 |
| 2020 | Research | $932,936 | 31 |
| 2019 | Research | $281,549 | 27 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- David Spigel Nashville, TN Named on 3 payments
- Sajeve Thomas Orlando, FL Named on 3 payments
- Walter Urba Portland, OR Named on 3 payments
- Gregory Daniels San Diego, CA Named on 2 payments
- Charles Cowey Dallas, TX Named on 2 payments
- Shailender Bhatia Seattle, WA Named on 2 payments
- Neil Belman Bethlehem, PA Named on 2 payments
- Luke Rothermel Cleveland, OH Named on 2 payments
- Mario Sznol New Haven, CT Named on 2 payments
- Douglas Johnson Nashville, TN Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.